The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Leading fiber broadband and technology provider Converge ICT Solutions Inc. (PSE: CNVRG) is enhancing its nationwide fiber network with an advanced data transmission technology from NASDAQ-listed ...

Hisense Broadband Multimedia Technologies Co., Ltd. (HBMT), a leading innovator of high-speed optical transceivers, active optical cables, ONTs and Terminal Devices, is pleased to announce the ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the ...

AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.

for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive, fatal heart disease. This decision comes after a Japanese Phase 3 study and the global ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company ... This study looked at the challenges of diagnosing cardiac transthyretin amyloidosis (cardiac ATTR) and how natural language processing ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.